NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.401) was uploaded to the NHS England Website on Friday 29, May 2026.
The following changes have been introduced:
Serplulimab in combination with carboplatin and etoposide (SER1)
For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Atezolizumab in combination with nab- paclitaxel (ATE6)
For treating untreated PD-L1-positive, triple negative, unresectable, locally advanced metastatic breast cancer for patients whose tumours express PD-L1 at a level of 1% or more where the following criteria have been met
Treatment criterion (#1 and 12) updated; Treatment criterion (#2 and 13) removed
NA (BRE3)
NA
Indication column updated; Treatment criterion (#1, 5 and 7) updated
NA (BRE5)
NA
Indication column updated; Treatment criterion (#1, 6 and 9) updated
Pertuzumab (PER2a)
Neoadjuvant pertuzumab plus trastuzumab in NODE POSITIVE patients for the neoadjuvant treatment of locally advanced, inflammatory or early breast cancer at high risk of recurrence (PER2a) where the following criteria have been met This form is for patients known to be pathologically node positive prior to commencing neo-adjuvant therapy. On commencing adjuvant treatment with pertuzumab, form PER4a (for node positive patients) must be completed. For patients with locally advanced, inflammatory or early breast cancer who are node negative of unknown nodal status when commencing neo- adjuvant pertuzumab, form PER2b must be used for the neoadjuvant part of treatment followed by form PER4b for the adjuvant part of treatment only if the histology post-surgery is node +ve.
Treatment criterion (#1 and 8) updated